Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

ABSTRACT: This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.

DISEASE(S): Dmmr Colorectal Cancer,Colon Cancer,Colonic Neoplasms

PROVIDER: 2404658 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR